Randomized trial of vigabatrin in patients with infantile spasms
- PMID:11673582
- DOI: 10.1212/wnl.57.8.1416
Randomized trial of vigabatrin in patients with infantile spasms
Abstract
Background: Infantile spasms are a rare but devastating pediatric epilepsy that, outside the United States, is often treated with vigabatrin. The authors evaluated the efficacy and safety of vigabatrin in children with recent-onset infantile spasms.
Methods: This 2-week, randomized, single-masked, multicenter study with a 3- year, open-label, dose-ranging follow-up study included patients who were younger than 2 years of age, had a diagnosed duration of infantile spasms of no more than 3 months, and had not previously been treated with adrenocorticotropic hormone, prednisone, or valproic acid. Patients were randomly assigned to receive low-dose (18-36 mg/kg/day) or high-dose (100-148 mg/kg/day) vigabatrin. Treatment responders were those who were free of infantile spasm for 7 consecutive days beginning within the first 14 days of vigabatrin therapy. Time to response to therapy was evaluated during the first 3 months, and safety was evaluated for the entire study period.
Results: Overall, 32 of 142 patients who were able to be evaluated for efficacy were treatment responders (8/75 receiving low-dose vigabatrin vs 24/67 receiving high doses, p < 0.001). Response increased dramatically after approximately 2 weeks of vigabatrin therapy and continued to increase over the 3-month follow-up period. Time to response was shorter in those receiving high-dose versus low-dose vigabatrin (p = 0.04) and in those with tuberous sclerosis versus other etiologies (p < 0.001). Vigabatrin was well tolerated and safe; only nine patients discontinued therapy because of adverse events.
Conclusions: These results confirm previous reports of the efficacy and safety of vigabatrin in patients with infantile spasms, particularly among those with spasms secondary to tuberous sclerosis.
Comment in
- Randomized trial of vigabatrin in patients with infantile spasms.Lux AL, Edwards SW, Osborne JP, Hancock E, Johnson AL, Verity CM, Kennedy CR, O'Callaghan FJ, Newton RW.Lux AL, et al.Neurology. 2002 Aug 27;59(4):648. doi: 10.1212/wnl.59.4.648.Neurology. 2002.PMID:12196676No abstract available.
Similar articles
- Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial.O'Callaghan FJK, Edwards SW, Alber FD, Cortina Borja M, Hancock E, Johnson AL, Kennedy CR, Likeman M, Lux AL, Mackay MT, Mallick AA, Newton RW, Nolan M, Pressler R, Rating D, Schmitt B, Verity CM, Osborne JP; International Collaborative Infantile Spasms Study (ICISS) investigators.O'Callaghan FJK, et al.Lancet Child Adolesc Health. 2018 Oct;2(10):715-725. doi: 10.1016/S2352-4642(18)30244-X. Epub 2018 Aug 29.Lancet Child Adolesc Health. 2018.PMID:30236380Clinical Trial.
- Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis.Chiron C, Dumas C, Jambaqué I, Mumford J, Dulac O.Chiron C, et al.Epilepsy Res. 1997 Jan;26(2):389-95. doi: 10.1016/s0920-1211(96)01006-6.Epilepsy Res. 1997.PMID:9095401Clinical Trial.
- Vigabatrin as First-Line Treatment for Infantile Spasms Not Related to Tuberous Sclerosis Complex.Jones K, Go C, Boyd J, Ochi A, McCoy B, Puka K, Snead OC 3rd.Jones K, et al.Pediatr Neurol. 2015 Aug;53(2):141-5. doi: 10.1016/j.pediatrneurol.2015.04.012. Epub 2015 Apr 30.Pediatr Neurol. 2015.PMID:26227562
- Vigabatrin for infantile spasms.Pesaturo KA, Spooner LM, Belliveau P.Pesaturo KA, et al.Pharmacotherapy. 2011 Mar;31(3):298-311. doi: 10.1592/phco.31.3.298.Pharmacotherapy. 2011.PMID:21361740Review.
- A risk-benefit assessment of treatments for infantile spasms.Nabbout R.Nabbout R.Drug Saf. 2001;24(11):813-28. doi: 10.2165/00002018-200124110-00003.Drug Saf. 2001.PMID:11665869Review.
Cited by
- Treatment of infantile spasms.Hancock EC, Osborne JP, Edwards SW.Hancock EC, et al.Cochrane Database Syst Rev. 2013 Jun 5;2013(6):CD001770. doi: 10.1002/14651858.CD001770.pub3.Cochrane Database Syst Rev. 2013.PMID:23740534Free PMC article.Review.
- Tuberous Sclerosis: A New Frontier in Targeted Treatment of Autism.Davis PE, Peters JM, Krueger DA, Sahin M.Davis PE, et al.Neurotherapeutics. 2015 Jul;12(3):572-83. doi: 10.1007/s13311-015-0359-5.Neurotherapeutics. 2015.PMID:25986747Free PMC article.Review.
- Use of second-generation antiepileptic drugs in the pediatric population.Chung AM, Eiland LS.Chung AM, et al.Paediatr Drugs. 2008;10(4):217-54. doi: 10.2165/00148581-200810040-00003.Paediatr Drugs. 2008.PMID:18590343Review.
- Infantile spasms: little seizures, BIG consequences.Shields WD.Shields WD.Epilepsy Curr. 2006 May-Jun;6(3):63-9. doi: 10.1111/j.1535-7511.2006.00100.x.Epilepsy Curr. 2006.PMID:16761063Free PMC article.
- Treatment of infantile spasms: the ideal and the mundane.Baram TZ.Baram TZ.Epilepsia. 2003 Aug;44(8):993-4. doi: 10.1046/j.1528-1157.2003.44086.x.Epilepsia. 2003.PMID:12887429Free PMC article.No abstract available.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources